Literature DB >> 16356002

Squaric acid-based peptidic inhibitors of matrix metalloprotease-1.

M Burak Onaran1, Anthony B Comeau, Christopher T Seto.   

Abstract

[structure: see text] A series of squaric acid-peptide conjugates were synthesized and evaluated as inhibitors of MMP-1. The cyclobut-3-enedione core was substituted at the 3-position with several functional groups, such as -N(alkyl)OH, -NHOH, and -OH, that are designed to bind to the zinc atom in the active site of the metalloprotease. The 4-position of the cyclobut-3-enedione was derivatized with mono- or dipeptides that are designed to bind in the S1' and S2' subsites of the enzyme, and position the metal chelating group appropriately in the active site for binding to zinc. Positional scanning revealed that -N(Me)OH provided the highest level of inhibition among the chelating groups that were tested, and Leu-Tle-NHMe was the preferred amino acid sequence. A combination of these groups yielded an inhibitor with an IC50 value of 95 microM. For one inhibitor, conversion of one of the carbonyl groups on the cyclobut-3-enedione core to a thiocarbonyl group resulted in a 18-fold increase in potency, and yielded a compound with an IC50 value of 15 microM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356002      PMCID: PMC2527039          DOI: 10.1021/jo0517848

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  23 in total

1.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis.

Authors:  W Lee; S Aitken; J Sodek; C A McCulloch
Journal:  J Periodontal Res       Date:  1995-01       Impact factor: 4.419

3.  Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor.

Authors:  N Borkakoti; F K Winkler; D H Williams; A D'Arcy; M J Broadhurst; P A Brown; W H Johnson; E J Murray
Journal:  Nat Struct Biol       Date:  1994-02

Review 4.  Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation.

Authors:  C Jackson; M Nguyen; J Arkell; P Sambrook
Journal:  Inflamm Res       Date:  2001-04       Impact factor: 4.575

5.  Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.

Authors:  Z P Kortylewicz; R E Galardy
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

Review 6.  Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome.

Authors:  Charles B Jones; David C Sane; David M Herrington
Journal:  Cardiovasc Res       Date:  2003-10-01       Impact factor: 10.787

7.  Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.

Authors:  Thierry Le Diguarher; Anne-Marie Chollet; Marc Bertrand; Philippe Hennig; Eric Raimbaud; Massimo Sabatini; Nicolas Guilbaud; Alain Pierré; Gordon C Tucker; Patrick Casara
Journal:  J Med Chem       Date:  2003-08-28       Impact factor: 7.446

8.  New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.

Authors:  David T Puerta; Jana A Lewis; Seth M Cohen
Journal:  J Am Chem Soc       Date:  2004-07-14       Impact factor: 15.419

9.  Squaryl group as a new mimic of phosphate group in modified oligodeoxynucleotides: synthesis and properties of new oligodeoxynucleotide analogues containing an internucleotidic squaryldiamide linkage.

Authors:  Kousuke Sato; Kohji Seio; Mitsuo Sekine
Journal:  J Am Chem Soc       Date:  2002-10-30       Impact factor: 15.419

10.  Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.

Authors:  W Liedtke; B Cannella; R J Mazzaccaro; J M Clements; K M Miller; K W Wucherpfennig; A J Gearing; C S Raine
Journal:  Ann Neurol       Date:  1998-07       Impact factor: 10.422

View more
  6 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

2.  Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors.

Authors:  Jacob D Durrant; César A F de Oliveira; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2011-06-20       Impact factor: 2.817

3.  Synthesis and evaluation of squaramide and thiosquaramide inhibitors of the DNA repair enzyme SNM1A.

Authors:  Mark Berney; William Doherty; Werner Theodor Jauslin; Manav T Manoj; Eva-Maria Dürr; Joanna Francelle McGouran
Journal:  Bioorg Med Chem       Date:  2021-08-25       Impact factor: 3.641

4.  Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.

Authors:  Jacob D Durrant; César Augusto F de Oliveira; J Andrew McCammon
Journal:  J Mol Recognit       Date:  2010 Mar-Apr       Impact factor: 2.137

5.  A hydroxamic-acid-containing nucleoside inhibits DNA repair nuclease SNM1A.

Authors:  William Doherty; Eva-Maria Dürr; Hannah T Baddock; Sook Y Lee; Peter J McHugh; Tom Brown; Mathias O Senge; Eoin M Scanlan; Joanna F McGouran
Journal:  Org Biomol Chem       Date:  2019-08-05       Impact factor: 3.876

6.  Examining the Impact of Squaric Acid as a Crosslinking Agent on the Properties of Chitosan-Based Films.

Authors:  Ewa Olewnik-Kruszkowska; Magdalena Gierszewska; Sylwia Grabska-Zielińska; Joanna Skopińska-Wiśniewska; Ewelina Jakubowska
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.